Physician profile
David P Nelson
NPI 1992878409
$2,522.83
in general payments reported to CMS, 2019-2025
13 companies · $715 in 2025
The $715 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $389 · 2021: $28.60 · 2022: $197 · 2023: $396 · 2024: $384 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,494.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $798.47 | 2019-2025 | Precision 1, Total30, Tryptyr |
| Coopervision INC. | $361.54 | 2019-2024 | Misight Contact Lens, Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $265.50 | 2019-2020 | |
| Allergan, INC. | $174.39 | 2022 | |
| Astellas Pharma US INC | $152.29 | 2024-2025 | Izervay |
| Optovue, INC. | $145.17 | 2020 | |
| Bausch & Lomb Americas INC. | $125.96 | 2025 | Infuse |
| Dompe US, INC. | $119.28 | 2025 | Oxervate |
| Lkc Technologies, INC. | $114.00 | 2023 | |
| Glaukos Corporation | $108.34 | 2025 | Idosetr |
| Optos, INC. | $76.96 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $58.31 | 2019-2025 | |
| Abbvie INC. | $22.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.